Loading clinical trials...
Loading clinical trials...
A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors.
Conditions
Interventions
SGR-3515
Locations
14
United States
Yale University, Yale Cancer Center
New Haven, Connecticut, United States
Northwestern University
Chicago, Illinois, United States
University of Michigan
Ann Arbor, Michigan, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Start Date
June 18, 2024
Primary Completion Date
October 31, 2026
Completion Date
December 31, 2026
Last Updated
August 1, 2025
NCT07177937
NCT07181681
NCT05919264
NCT06257264
NCT07387068
NCT07360314
Lead Sponsor
Schrödinger, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions